Celularity Inc. (GXGXW) Stock Analysis

Celularity Inc. (GXGXW) Healthcare & Pipeline Overview

Celularity Inc., operating within the biotechnology sector, focuses on placental-derived cellular medicines. With a gross margin of 55.3%, the company is developing therapies for cancer, infectious diseases, and degenerative diseases. Celularity's innovative platform aims to address unmet medical needs through cellular engineering and regenerative medicine.

What Is the Investment Thesis for GXGXW?

Celularity Inc. presents a high-risk, high-reward investment thesis centered on its innovative placental-derived cellular medicine platform. The company's potential lies in its ability to develop effective therapies for diseases with significant unmet needs. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. Celularity's gross margin of 55.3% indicates potential for profitability if clinical programs are successful. However, the company's negative P/E ratio of -0.40 and profit margin of -198.7% highlight the substantial financial risks associated with biotechnology companies in the clinical development stage. Upcoming clinical trial results and regulatory milestones represent key catalysts. Investors should carefully consider the inherent risks and uncertainties associated with Celularity's business model and clinical development programs.

Based on FMP financials and quantitative analysis

GXGXW Key Highlights

Market Cap of $238M reflects the company's current valuation in the biotechnology sector.

• Gross Margin of 55.3% indicates potential for profitability upon successful commercialization of products.
• P/E Ratio of -0.40 highlights the company's current lack of profitability due to ongoing research and development expenses.
• Profit Margin of -198.7% reflects significant investments in clinical trials and drug development.
• Focus on placental-derived cellular medicines positions the company in the innovative field of regenerative medicine.

Who Are GXGXW's Competitors?

GXGXW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GXGXW's Key Strengths?

Proprietary placental-derived cell therapy platform.

• Potential for breakthrough therapies in unmet medical needs.
• Experienced management team with expertise in cell therapy development.
• Gross margin of 55.3% indicates potential for profitability.

What Are GXGXW's Weaknesses?

Negative P/E ratio and profit margin reflect current lack of profitability.

• Reliance on clinical trial success and regulatory approvals.
• High cash burn rate due to ongoing research and development expenses.
• Limited commercial infrastructure.

What Could Drive GXGXW Stock Higher?

Clinical trial results for lead product candidates in cancer and infectious diseases.

• Regulatory submissions for potential approvals of cell therapies.
• Expansion of strategic partnerships with pharmaceutical companies.
• Advancements in manufacturing technologies to improve scalability.

What Are the Key Risks for GXGXW?

Financial-distress signal — its Altman Z-Score of -13.83 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $11.0M recently.
• Clinical trial failures and regulatory setbacks.
• Competition from other cell therapy companies.
• Changes in reimbursement policies.
• High cash burn rate due to ongoing research and development expenses.

What Are the Growth Opportunities for GXGXW?

• Expansion of Clinical Pipeline: Celularity has the opportunity to expand its clinical pipeline by developing new cell therapies and biomaterials for additional indications. The market for cell therapies is projected to reach $82.6 billion by 2030, offering a substantial growth opportunity for Celularity. Successful clinical trials and regulatory approvals will be critical for realizing this potential. Timeline: Ongoing clinical trials with potential for new programs initiated within the next 2-3 years.
• Strategic Partnerships: Celularity can pursue strategic partnerships with pharmaceutical companies, biotechnology companies, and academic institutions to accelerate the development and commercialization of its products. Collaborations can provide access to funding, expertise, and distribution channels. The market for pharmaceutical collaborations is estimated at $45 billion annually. Timeline: Ongoing discussions with potential partners, with potential for new agreements within the next 1-2 years.
• Geographic Expansion: Celularity has the opportunity to expand its geographic reach beyond the United States by entering new markets in Europe, Asia, and other regions. International expansion can increase the company's revenue and market share. The global market for cell therapies is growing rapidly, with significant opportunities in emerging markets. Timeline: Potential for expansion into Europe and Asia within the next 3-5 years.
• Advancements in Manufacturing: Celularity can invest in advanced manufacturing technologies to improve the scalability and efficiency of its cell therapy production. Streamlined manufacturing processes can reduce costs and increase the availability of its products. The market for cell therapy manufacturing is estimated at $12 billion. Timeline: Ongoing investments in manufacturing infrastructure, with potential for significant improvements within the next 2-3 years.
• Regulatory Approvals and Reimbursement: Celularity's growth is heavily dependent on obtaining regulatory approvals for its products and securing favorable reimbursement policies from payers. Successful regulatory outcomes and reimbursement coverage can drive adoption and market access. The market for reimbursed cell therapies is growing rapidly as new products are approved and covered by insurance. Timeline: Ongoing interactions with regulatory agencies and payers, with potential for approvals and reimbursement decisions within the next 1-2 years.

What Are GXGXW's Competitive Advantages?

• Proprietary placental-derived cell and biomaterial platform.
• Intellectual property protection for its cell therapies.
• Clinical data supporting the safety and efficacy of its products.
• Strategic partnerships with leading research institutions.

What Does GXGXW Do?

Celularity Inc., a biotechnology company, is dedicated to developing innovative cellular medicines derived from the placenta. Founded on the premise of harnessing the unique properties of placental cells, Celularity aims to address unmet medical needs in cancer, infectious diseases, and degenerative diseases. The company's platform leverages the placenta's rich source of stem cells and immune cells to create allogeneic cell therapies and biomaterials. Celularity's therapeutic pipeline includes programs targeting hematologic malignancies, solid tumors, and autoimmune disorders. The company's approach involves both unmodified and genetically modified placental-derived cells to enhance their therapeutic potential. Celularity's geographic reach is primarily focused on the United States, with potential for expansion into other markets as its clinical programs advance. Celularity competes with other biotechnology companies developing cell therapies and regenerative medicine products, striving to differentiate itself through its proprietary placental-derived platform and clinical development strategy. As of 2026, Celularity continues to advance its clinical programs and explore new applications for its cellular medicines.

What Products and Services Does GXGXW Offer?

• Develops placental-derived cell therapies for cancer.
• Creates treatments for infectious diseases using cellular medicines.
• Engineers cell therapies for degenerative diseases.
• Utilizes a proprietary placental-derived cell and biomaterial platform.
• Focuses on allogeneic cell therapies.
• Conducts clinical trials to evaluate the safety and efficacy of its products.
• Seeks regulatory approvals from the FDA and other agencies.

How Does GXGXW Make Money?

• Develops and manufactures cell therapies.
• Conducts clinical trials to demonstrate efficacy.
• Seeks regulatory approval for its therapies.
• Commercializes approved therapies through direct sales and partnerships.

What Industry Does GXGXW Operate In?

Celularity Inc. operates within the biotechnology industry, a sector characterized by rapid innovation, high risk, and significant potential for reward. The market for cell therapies and regenerative medicine is growing, driven by advances in biotechnology and increasing demand for novel treatments for chronic diseases. Celularity competes with other biotechnology companies, pharmaceutical companies, and academic institutions in the development of cell therapies and related products. The industry is subject to stringent regulatory requirements and faces challenges related to clinical trial success, manufacturing scalability, and market access. Celularity's placental-derived platform positions it within a niche segment of the cell therapy market.

Who Are GXGXW's Key Customers?

• Patients with cancer.
• Patients with infectious diseases.
• Patients with degenerative diseases.
• Hospitals and clinics that administer cell therapies.
• Research institutions involved in clinical trials.

Celularity Inc. Financial Trajectory

Celularity Inc. (GXGXW) reported $4.1M in revenue for Q4 2025, a decline of 22.3% compared to the prior quarter. The company recorded a net loss of $24.4M, with diluted EPS of $-0.95. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, GXGXW averaged $-0.92 in diluted EPS.

Company Profile

Celularity Inc. operates in the Biotechnology industry within the Healthcare sector. GXGXW has traded publicly since 2019.

How Celularity Inc. Is Valued

Celularity Inc. carries a market capitalization of $238M, placing it in the micro-cap category.

Return on equity for Celularity Inc. stands at 411.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -85.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching.

Celularity Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.83 places it in the distress zone, a signal of elevated financial risk.

Over the past six months, Celularity Inc. insiders filed 15 SEC Form 4 transactions — 12 sales and 3 purchases. On net that is roughly 6.1M shares disposed (about $11.0M), a signal worth weighing alongside the fundamentals.

GXGXW Financials

GXGXW Latest News

No recent news available for GXGXW.

Celularity Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources